Key result
Cardiovascular prevention drugs may modulate platelet-derived microvesicle release and surface molecule expression.
Answers are grounded in this paper and cite their sources.
Platelet-derived microvesicles (pMVs) are small, heterogeneous vesicles released from platelet membranes as a result of activation. These microvesicles possess a wide range of properties, including prothrombotic, proatherogenic, proinflammatory, immunomodulatory, and even anticoagulant activity. The elevated release of these microvesicles has been observed in various metabolic, inflammatory, thrombotic, and vascular diseases, including ischemic heart disease, stroke, hypertension, diabetes, and connective tissue disease. Modulation of both pMV generation and the expression of their surface molecules may have beneficial clinical implications and could become a novel therapeutic target. However, mechanisms by which pharmacological agents can modify pMV formation are elusive. The purpose of this review is to discuss the effects of drugs routinely used in primary and secondary prevention of vascular disease on the release of pMV and expression of their surface procoagulant and proinflammatory molecules.
No takes yet. Share an insight, caveat, or question.
Rosińska et al. (2017) conducted a review in Vascular disease (including ischemic heart disease, stroke, hypertension, diabetes, and connective tissue disease). Drugs routinely used in primary and secondary prevention of vascular disease was evaluated on Release of platelet-derived microvesicles (pMVs) and expression of their surface procoagulant and proinflammatory molecules. Pharmacological agents for vascular disease prevention may modulate platelet-derived microvesicle release and surface molecule expression (narrative review; no quantitative results reported).
Synapse has enriched 10 related papers. Consider them for comparative context: